Answer
It is unknown whether CARVYKTI (ciltacabtagene autoleucel) passes into human breast milk; breastfeeding women should be advised of potential risks to the infant, and breastfeeding after administration should be discussed with the treating physician.
Sources for this answer
- CARVYKTI 3.2 × 10^6 – 1 × 10^8 cells dispersion for infusionJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 6Document updated
Sources checked